Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 11/20 | 0.52 |
| ▸ | MERTK | Q12866 | 7/20 | 0.52 |
| ▸ | RORC | P51449 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 4/20 | 0.45 |
| ▸ | TYRO3 | Q06418 | 4/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18044576 | 0.85 | AXL (0.60) | AXLMERTKFLT3MET | |
| SCHEMBL18044580 | 0.79 | HCK (0.50) | AXLMERTKFLT3METPDPK1 | |
| SCHEMBL18044635 | 0.79 | SRC (0.49) | AXLMERTKFLT3METTYRO3 | |
| SCHEMBL18044636 | 0.79 | SRC (0.49) | AXLMERTKFLT3METTYRO3 | |
| SCHEMBL20335586 | 0.79 | SRC (0.49) | AXLMERTKFLT3METTYRO3 | |
| SCHEMBL22930440 | 0.76 | PIK3CD (0.57) | AXLRORCFLT3METPIK3CD | |
| SCHEMBL20335585 | 0.76 | AXL (0.63) | AXLMERTKFLT3METPDPK1 | |
| SCHEMBL18044608 | 0.76 | AXL (0.49) | AXLMERTKFLT3MET | |
| SCHEMBL16709457 | 0.76 | AXL (0.63) | AXLMERTKFLT3METPDPK1 | |
| SCHEMBL18044595 | 0.75 | AXL (0.57) | AXLMERTKFLT3MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3067356-B1 | PYRROLO PYRIMIDINE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2018-07-04 | — | — | EP | disclosed |
| US-9586967-B2 | Pyrrolo pyrimidine derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-03-07 | — | — | US | disclosed |
| US-20160264579-A1 | PYRROLO PYRIMIDINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-09-15 | — | — | US | disclosed |
| EP-3067356-A1 | PYRROLO PYRIMIDINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2016-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264579-A1 | PYRROLO PYRIMIDINE DERIVATIVE | AXL, FLT3, TYRO3 | AXL 1/4885MERTK 5/4885RORC 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.